SCHEMBL318666

SCHEMBL318666

O=c1n(CCCOc2cccc(Cl)c2)nc2ccc(-c3ccc(OC(F)(F)F)cc3)cn12

nearest known ligand 0.54

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SCN5A Q14524 12/20 0.54
SCN1A P35498 2/20 0.50
SCN2A Q99250 2/20 0.50
GPR139 Q6DWJ6 3/20 0.41
TRPA1 O75762 1/20 0.39
KDM4E B2RXH2 1/20 0.38
ABCB11 O95342 1/20 0.38
ALDH1A1 P00352 1/20 0.38
LMNA P02545 1/20 0.38
HTR1A P08908 1/20 0.38
ADRA2A P08913 1/20 0.38
CYP2D6 P10635 1/20 0.38
DRD2 P14416 1/20 0.38
HPGD P15428 1/20 0.38
ADRA2B P18089 1/20 0.38
ADRA2C P18825 1/20 0.38
DRD1 P21728 1/20 0.38
DRD4 P21917 1/20 0.38
HRH2 P25021 1/20 0.38
ADRA1D P25100 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL318179 0.95 SCN5A (0.55) SCN5ASCN1ASCN2AGPR139LMNA
SCHEMBL252156 0.88 SCN5A (0.57) SCN5ASCN1ASCN2AGPR139HRH2
SCHEMBL253071 0.84 SCN5A (0.57) SCN5ASCN1ASCN2AGPR139
SCHEMBL318478 0.84 SCN5A (0.57) SCN5ASCN1ASCN2AGPR139
SCHEMBL253418 0.84 SCN5A (0.53) SCN5ASCN1ASCN2AGPR139KDM4E
SCHEMBL252292 0.83 SCN5A (0.58) SCN5ASCN1ASCN2AGPR139
SCHEMBL253978 0.82 SCN5A (0.59) SCN5ASCN1ASCN2AGPR139
SCHEMBL251271 0.81 SCN5A (0.54) SCN5ASCN1ASCN2AGPR139KCNH2
SCHEMBL253060 0.81 SCN5A (0.53) SCN5ASCN1ASCN2AGPR139
SCHEMBL254103 0.80 SCN5A (0.55) SCN5ASCN1ASCN2AGPR139MCHR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9079901-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2015-07-14 US disclosed
US-20150080370-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS GILEAD SCIENCES, INC. 2015-03-19 US disclosed
US-8703759-B2 Fused heterocyclic compounds as ion channel modulators GILEAD SCIENCES, INC. (US) 2014-04-22 US disclosed
US-20120010192-A1 Fused Heterocyclic Compounds as Ion Channel Modulators GILEAD SCIENCES, INC. 2012-01-12 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20150080370-A1 FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS KCNJ2, KCNH2, CACNA1E SCN5A 37/4885SCN1A 43/4885SCN2A 55/4885
US-20120010192-A1 Fused Heterocyclic Compounds as Ion Channel Modulators KCNJ2, KCNH2, CACNA1E SCN5A 37/4885SCN1A 43/4885SCN2A 55/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.